为瘤学应用设计的多功能转化生长因子-β II 型受体ectodomain融合
Anne E G Lenferink1, John C Zwaagstra2, Jason Baardsnes2
1Medical Devices Research Centre, National Research Council Canada, Montréal, QC, Canada.
Frontiers in oncology
|November 12, 2025
概括
研究人员通过将TGF-βII型受体ectodomain (TβRII-ED) 与抗体融合,开发了新的转化生长因子-β (TGF-β) 治疗方法. 这些TβRII-ED-Fc融合有效地捕获TGF-β,为癌症治疗提供了一个有前途的策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 转化生长因子-β (TGF-β) 在癌症中起着双重作用,在早期起到瘤抑制作用,但在晚期促进瘤发生,转移和化学抵抗.
- 对于开发有效的向疗法而言,TGF-β的向性质构成了重大挑战.
研究的目的:
- 设计和开发一种新型的TGF-β向生物治疗药物.
- 为了创建融合蛋白质,将TGF-βII型受体ectodomain (TβRII-ED) 与针对癌症治疗的抗体片段结合起来.
主要方法:
- 构建和表征了TβRII-ED-Fc融合蛋白.
- 评估了对不同TGF-β异型的融合的体外中和作用.
- 评估了TβRII-ED-Fc在中和促进瘤TGF-β活动中的体内功效.
主要成果:
- TβRII-ED-Fc融合证明了高效的TGF-β连接物捕获,具有对TGF-β1和TGF-β3异型的皮科马尔强度.
- 当与准部分组合在一起时,TβRII-ED-Fc模块证明了它的多功能性.
- 这些向的融合在体内有效地中和了促进瘤的TGF-β活动.
结论:
- TβRII-ED-Fc融合蛋白代表了一种新且强效的TGF-β向治疗药物.
- 这种多功能联结体捕获模块可以被设计成强大的抗癌生物疗法.
- 向的输送和瘤部位的保留增强了这些药物的治疗潜力.
更多相关视频
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
666
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
719
相关概念视频
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
01:16TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
01:15Receptor Downregulation in MVBs
2.7K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:26Receptor Tyrosine Kinases
17.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
17.8K